Regeneron and Sanofi's Dupixent shows treatment benefit in adolescents with atopic dermatitis [Seeking Alpha]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Seeking Alpha
Regeneron Pharmaceuticals (NASDAQ: REGN ) and development partner Sanofi (NYSE: SNY ) announce detailed results from a Phase 3 clinical trial evaluating Dupixent (dupilumab) in adolescents (ages 12 - 17 years) with moderate-to-severe atopic dermatitis (AD). The data were presented at the EADV Congress in Paris. The co-primary endpoint ex-U.S. was the proportion of patients achieving EASI-75 (75% improvement in symptoms) while the primary endpoint in the U.S. was the proportion of patients achieving IGA 0 (clear skin) or 1 (almost clear). 41.5% of patients receiving Dupixent every two weeks and 38% of those receiving the drug every four weeks achieved EASI-75 compared to 8% for placebo (p 24% of patients receiving weight-based dosing of Dupixent every two weeks and 18% of those receiving a fixed-dose regimen every four weeks achieved IGA 0 or 1 compared to 2% for placebo (p Key secondary endpoints were also met. On the safety front, adverse events (AEs) were observe
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- UPDATE 1-European stocks slip as mixed earnings offset M&A cheer [Yahoo! Finance]Yahoo! Finance
- Life Sciences Market To Reach USD 9.6 Billion By 2032, Says DataHorizzon Research [Yahoo! Finance]Yahoo! Finance
- Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio [Yahoo! Finance]Yahoo! Finance
- Sanofi Posts Strong Sales Growth With New Hemophilia Medicine [BNN Bloomberg (Canada)]BNN Bloomberg
- Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance [Yahoo! Finance]Yahoo! Finance
SNY
Analyst Actions
- 2/12/24 - TheStreet
SNY
Sec Filings
- 4/4/24 - Form F-3ASR
- 4/4/24 - Form S-8
- 3/20/24 - Form 6-K
- SNY's page on the SEC website